Epstein-Barr virus-associated malignancies

• Published in: Critical reviews in clinical laboratory sciences Vol. 25; no. 2; p. 105
• Main Authors: Richtsmeier, W J, Wittels, E G, Mazur, E M
• Format: Journal Article
• Language: English
• Published: England 1987
• Subjects: Burkitt Lymphoma - microbiology; Carcinoma - etiology; Herpesvirus 4, Human - pathogenicity; Humans; Nasopharyngeal Neoplasms - etiology; Tumor Virus Infections - complications
• ISSN: 1040-8363; 1549-781X
• DOI: 10.3109/10408368709105879

The infectious aspects of cancer in humans were epidemiologically pioneered by Dr. David Burkitt through his observations of lymphomatous tumors seen in children in equatorial Africa. Years, later, the Epstein-Barr virus (EBV) was shown to be intimately associated with such tumors and is now recognized as a component of some B-cell lymphomas and nasopharyngeal carcinoma. Still the questions of an active, passive, or accessory role persist. The ability of this virus to cause immunosuppressive hemopoietic disturbances in individuals infected with EBV but not developing cancer raise questions about host susceptibility, host immune response, and possible coconspiring, infectious, oncogenic agents. Recent associations of EBV antibody found in diseases, such as squamous cell carcinoma of the head and neck and acquired immunodeficiency syndromes, point to its possible accessory role as an immunosuppressive agent. The ability of EBV to spread by extracellular and intracellular mechanisms demonstrates its variable infectious potential. Numerous EBV-transformed human cell lines attest to its ability to confer "immortality" with uncontrolled growth patterns. This review critically examines the association of EBV with various malignancies, the type of evidence which links it there, and the implications for further investigations and therapy.